Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2021 and provided a business update.
2021 Highlights
Raised gross proceeds of $94 million in an initial public offering (IPO); cash runway sufficient to fund planned operations into 2024
Fast Track Designation granted in the U.S. for REN001 in primary mitochondrial myopathy (PMM)
Initiated enrollment of STRIDE, a global, double-blind, randomized, placebo-controlled Phase 2b clinical trial of REN001 in patients with PMM
Initiated STRIDE AHEAD, an open-label extension safety trial of REN001 in patients with PMM
Completed enrollment of open-label Phase 1b clinical trials in patients with McArdle disease and patients with long-chain fatty acid oxidation disorders (LC-FAOD), as well as the FORWARD natural history study in patients with LC-FAOD
Received a notice of allowance from the U.S. Patent and Trademark Office for a composition of matter patent, which provides exclusivity for REN001 in the U.S. into 2041
Appointed Ashley Hall, J.D. as Chief Development Officer and Eric Dube, Ph.D., President & CEO of Travere Therapeutics, to the Board of Directors
“2021 was a transformational year for Reneo, highlighted by our debut as a public company and the significant progress we made on our REN001 clinical programs,” said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. “Despite the persistent challenges associated with the global COVID-19 pandemic, we made good progress with enrollment of our pivotal PMM study and completed enrollment of three other clinical studies, including the exploratory Phase 1b trials in McArdle disease and LC-FAOD. Furthermore, we expanded our intellectual property portfolio in the U.S. and strengthened our rare disease capabilities by making key additions to the Executive Team and the Board of Directors. Finally, we ended the year with approximately $147 million in cash and investments which will fund the company through the completion of our pivotal PMM study and into 2024.”
Clinical Update
PMM Program
Completed analysis of muscle biopsies from the PMM Phase 1b study which showed an increase in the expression of genes involved with the transport and metabolism of nutrients in the mitochondria
The STRIDE study is currently enrolling patients at 33 trials sites in 13 countries
Completion of STRIDE enrollment is anticipated by year-end 2022, with data in 2023
LC-FAOD Program
21 patients were enrolled in the 12-week open-label LC-FAOD Phase 1b study
61 patients were enrolled in the 4-month FORWARD study
Results of both LC-FAOD studies anticipated in 2Q 2022
McArdle Disease Program
17 patients were enrolled in the 12-week open-label McArdle Phase 1b study
REN001 was generally well tolerated with no drug related serious adverse events observed
The most common treatment-emergent adverse events were headache, influenza, and increased creatine phosphokinase, the majority reported to be mild in severity
Baseline 12-minute shuttle walk test (12MSWT) distance was 933 meters
An increase of 25 meters in the 12MSWT was observed at week 12, with no corresponding change in heart rate, fatigue, or pain
An increase of 38.5% in fat oxidation as measured by indirect calorimetry was observed at week 12
Based on the results, Reneo does not intend to pursue a subsequent Phase 2 study in McArdle Disease
Mr. Flesher continued, “We are pleased to see good safety and tolerability of REN001 in McArdle patients, as well as the substantial increase in fatty acid oxidation, a finding that is consistent with our prior clinical experience and encouraging as it relates to the ongoing PMM program. We also saw a modest increase in walk distance, but did not see a corresponding reduction in the common symptoms that McArdle patients experience. Given these findings, we will focus REN001 development on PMM and LC-FAOD, and will continue to explore other diseases that are defined by the impairment of mitochondria to produce cellular energy. We are grateful to the patients, families, and caregivers who made this study in McArdle disease possible,” concluded Mr. Flesher.
Financial Results for Fourth Quarter and Full Year 2021
The company reported a net loss of $10.6 million, or $0.43 per share, during the fourth quarter of 2021, compared to a net loss of $6.3 million, or $3.05 per share, for the same period in 2020. For the full year 2021, Reneo reported a net loss of $39.8 million, or $2.19 per share, compared to a net loss of $19.5 million, or $9.60 per share for the same period in 2020. The company had $147.7 million in cash, cash equivalents and short-term investments as of December 31, 2021.
Research and development (R&D) expenses were $7.1 million during the fourth quarter of 2021, compared to $5.1 million for the same period in 2020. For the full year 2021, R&D expenses were $28.2 million, compared to $15.9 million for the same period in 2020. The increase in R&D expense for 2021 was primarily due to an increase of $5.7 million related to clinical and manufacturing activities for REN001, $3.0 million in personnel related costs due to support growth in its development activities, and $2.0 million in milestone costs under the vTv Therapeutics License Agreement, offset by a $1.5 million tax rebate received in 2020 from the U.K. government for qualifying research expense incurred in the U.K.
General and administrative (G&A) expenses were $3.5 million during the fourth quarter of 2021, compared to $1.1 million for the same period in 2020. For the full year 2021, G&A expenses were $11.6 million, compared to $3.6 million for the same period in 2020. The increase in G&A expenses for 2021 was primarily as a result of its IPO in April 2021 and increased operating activities necessary to operate as a public company, which consisted of increases in personnel-related expenses of $5.1 million, insurance premiums of $1.1 million, and outside professional services of $1.3 million.
Corporate Access Events
H.C. Wainwright Global Investment Conference, May 23-26, 2022
Jefferies Healthcare Conference, June 8-10, 2022
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
About REN001
REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). For more information on REN001 clinical trials, please see clinicaltrials.gov.
About PMM
PMM are a group of disorders caused by genetic mutations within the mitochondrial DNA or nuclear DNA that affect the activity of enzymes or other proteins in the mitochondria. In PMM these genetic alterations hamper the ability of mitochondria to generate energy from nutrient sources, resulting in energy deficits that are most pronounced in tissues with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness or exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.
About STRIDE
STRIDE is a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to assess the efficacy and safety of 100 mg REN001 administered orally once daily to patients with PMM. Approximately 200 adult PMM patients with alterations in mitochondrial DNA and a history of myopathy are expected to be enrolled into STRIDE. The primary efficacy endpoint of the trial is the change from baseline in the distance walked during a 12-minute walk test (12MWT) after 24 weeks of treatment. Secondary efficacy endpoints include changes from baseline in the Modified Fatigue Impact Scale (MFIS), Patient Global Impression of Change scale (PGIC), and other patient-reported outcomes.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Reneo’s clinical trials, presentation of data from clinical trials, the regulatory approval path for REN001 intellectual property protection matters, the strength of Reneo’s balance sheet and the adequacy of cash on hand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
RENEO PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value and share data)
December 31, | December 31, | |||||||
2021 | 2020 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 124,660 | $ | 53,613 | ||||
Short-term investments | 23,010 | — | ||||||
Prepaid expenses and other current assets | 6,064 | 1,412 | ||||||
Total current assets | 153,734 | 55,025 | ||||||
Property and equipment, net | 212 | 69 | ||||||
Other non-current assets | 78 | 127 | ||||||
Total assets | $ | 154,024 | $ | 55,221 | ||||
Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 2,022 | $ | 908 | ||||
Accrued expenses | 4,180 | 3,672 | ||||||
Total current liabilities | 6,202 | 4,580 | ||||||
Deferred rent | 167 | 36 | ||||||
Performance award | 444 | — | ||||||
Total liabilities | 6,813 | 4,616 | ||||||
Commitments and contingencies | ||||||||
Series A convertible preferred stock, $0.0001 par value; zero and 24,302,472 shares authorized and outstanding at December 31, 2021 and 2020, | ||||||||
respectively; liquidation preference of $0 and $49,127 at December 31, 2021 and 2020, respectively | — | 45,652 | ||||||
Series B convertible preferred stock, $0.0001 par value; zero and 46,881,028 shares authorized at December 31, 2021 and 2020, respectively; zero and | ||||||||
23,440,514 shares issued and outstanding at December 31, 2021 and 2020, respectively; liquidation preference of $0 and $47,385 as of December 31, 2021 and 2020, respectively | — | 47,068 | ||||||
Stockholders’ equity (deficit): | ||||||||
Common stock, $0.0001 par value; 200,000,000 and 105,000,000 shares authorized at December 31, 2021 and 2020, respectively; 24,457,838 shares and | ||||||||
24,455,390 issued and outstanding at December 31, 2021, respectively; and 2,053,070 shares issued and outstanding at December 31, 2020 | 3 | — | ||||||
Additional paid-in capital | 231,902 | 2,843 | ||||||
Accumulated deficit | (84,728 | ) | (44,958 | ) | ||||
Accumulated other comprehensive income | 34 | — | ||||||
Total stockholders’ equity (deficit) | 147,211 | (42,115 | ) | |||||
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 154,024 | $ | 55,221 | ||||
RENEO PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||
Operating expenses: | (Unaudited) | ||||||||||||||
Research and development | $ | 7,100 | $ | 5,118 | $ | 28,169 | $ | 15,944 | |||||||
General and administrative | 3,524 | 1,133 | 11,649 | 3,608 | |||||||||||
Total operating expenses | 10,624 | 6,251 | 39,818 | 19,552 | |||||||||||
Loss from operations | (10,624 | ) | (6,251 | ) | (39,818 | ) | (19,552 | ) | |||||||
Other income (loss) | 17 | (2 | ) | 48 | 87 | ||||||||||
Net loss | (10,607 | ) | (6,253 | ) | (39,770 | ) | (19,465 | ) | |||||||
Unrealized gain (loss) on short-term investments | 17 | (3 | ) | 34 | (3 | ) | |||||||||
Comprehensive loss | $ | (10,590 | ) | $ | (6,256 | ) | $ | (39,736 | ) | $ | (19,468 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.43 | ) | $ | (3.05 | ) | $ | (2.19 | ) | $ | (9.60 | ) | |||
Weighted-average shares used in computing net loss per share, basic and diluted | 24,427,455 | 2,049,550 | 18,143,487 | 2,028,198 | |||||||||||
RENEO PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Year Ended | ||||||||
December 31, | ||||||||
2021 | 2020 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (39,770 | ) | $ | (19,465 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 50 | 37 | ||||||
Amortization/accretion on short-term investments | 202 | (17 | ) | |||||
Changes in the fair value of performance award | 444 | — | ||||||
Loss on disposal of property, plant & equipment | — | 2 | ||||||
Stock-based compensation | 3,891 | 393 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts payable, accrued expenses and other | 1,780 | 1,486 | ||||||
Prepaid expenses and other assets | (4,711 | ) | (967 | ) | ||||
Deferred rent | 131 | (5 | ) | |||||
Net cash used in operating activities | (37,983 | ) | (18,536 | ) | ||||
Cash flows from investing activities | ||||||||
Purchases of property and equipment | (198 | ) | (24 | ) | ||||
Purchase of available-for-sale short-term investments | (31,406 | ) | — | |||||
Proceeds from maturities of available-for-sale short-term investments | 8,228 | 7,400 | ||||||
Net cash (used in) provided by investing activities | (23,376 | ) | 7,376 | |||||
Cash flows from financing activities | ||||||||
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs | 47,238 | 47,185 | ||||||
Proceeds from initial public offering, net of offering costs | 84,612 | — | ||||||
Proceeds from issuance of common stock pursuant to equity award plans | 556 | 87 | ||||||
Net cash provided by financing activities | 132,406 | 47,272 | ||||||
Effect of exchange rates on cash and cash equivalents | — | |||||||
Net increase in cash and cash equivalents | 71,047 | 36,112 | ||||||
Cash and cash equivalents, beginning of period | 53,613 | 17,501 | ||||||
Cash and cash equivalents, end of period | $ | 124,660 | $ | 53,613 | ||||
Supplemental cash flow information: | ||||||||
Vesting of unvested exercised options | $ | 4 | $ | — | ||||
Unpaid Series B convertible preferred stock issuance costs | $ | — | $ | 117 | ||||
Costs incurred in connection with initial public offering included in accrued expenses | $ | — | $ | 33 | ||||
Property and equipment in accounts payable | $ | — | $ | 5 | ||||
Contacts:
Joyce Allaire |
